# Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Study · id `cardio:ct-nct01730053` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01730053](<https://clinicaltrials.gov/study/NCT01730053>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01730053

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.

## Technical summary

Registry record NCT01730053. Randomized; quadruple masking; primary purpose treatment. Start 2012-11-30 (actual); primary completion 2014-04-30 (actual). Results posted on 2015-10-28.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 305 participants (enrolled count; ClinicalTrials.gov record NCT01730053, source copy `cardio:ctgov-nct01730053-2020-04-07`, retrieved 2026-10-31)
- Started: 2012-11-30 (actual) (ClinicalTrials.gov record NCT01730053, source copy `cardio:ctgov-nct01730053-2020-04-07`, retrieved 2026-10-31)
- Primary completion: 2014-04-30 (actual) (ClinicalTrials.gov record NCT01730053, source copy `cardio:ctgov-nct01730053-2020-04-07`, retrieved 2026-10-31)
- Completion: 2014-05-31 (actual) (ClinicalTrials.gov record NCT01730053, source copy `cardio:ctgov-nct01730053-2020-04-07`, retrieved 2026-10-31)
- Results first posted: 2015-10-28 (ClinicalTrials.gov record NCT01730053, source copy `cardio:ctgov-nct01730053-2020-04-07`, retrieved 2026-10-31)
- Countries: United States; Australia; Canada; France; Germany; Italy; Mexico; Spain; United Kingdom (ClinicalTrials.gov record NCT01730053, source copy `cardio:ctgov-nct01730053-2020-04-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01730053-2020-04-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)
- Condition: Hypercholesterolemia
- Intervention (Drug): Alirocumab
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Ezetimibe
- Intervention (Drug): Placebo
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial (`cardio:pubmed-26638010`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 15c937967ca9a60985800838206dcc6b3eb25e5eb24c831155eb9516b81dec8e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
